Australia markets close in 1 hour 25 minutes

Australian Clinical Labs Limited (ACL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
2.4250-0.0050 (-0.21%)
As of 02:17PM AEST. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) 490.46M
Enterprise value 792.55M
Trailing P/E 31.72
Forward P/E 12.87
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.74
Price/book (mrq)2.98
Enterprise value/revenue 1.19
Enterprise value/EBITDA 5.15

Trading information

Stock price history

Beta (5Y monthly) 1.19
52-week change 3-30.57%
S&P500 52-week change 326.43%
52-week high 33.6700
52-week low 32.2600
50-day moving average 32.5412
200-day moving average 32.7754

Share statistics

Avg vol (3-month) 3514.38k
Avg vol (10-day) 3402.4k
Shares outstanding 5201.83M
Implied shares outstanding 6205.99M
Float 8107.62M
% held by insiders 113.50%
% held by institutions 173.61%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.1
Forward annual dividend yield 44.12%
Trailing annual dividend rate 30.10
Trailing annual dividend yield 34.12%
5-year average dividend yield 4N/A
Payout ratio 4182.77%
Dividend date 3N/A
Ex-dividend date 428 Mar 2024
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 2.29%
Operating margin (ttm)6.95%

Management effectiveness

Return on assets (ttm)5.58%
Return on equity (ttm)9.19%

Income statement

Revenue (ttm)674.03M
Revenue per share (ttm)3.36
Quarterly revenue growth (yoy)-6.40%
Gross profit (ttm)N/A
EBITDA 66.57M
Net income avi to common (ttm)15.43M
Diluted EPS (ttm)0.0800
Quarterly earnings growth (yoy)-80.50%

Balance sheet

Total cash (mrq)25.59M
Total cash per share (mrq)0.13
Total debt (mrq)327.03M
Total debt/equity (mrq)198.17%
Current ratio (mrq)0.66
Book value per share (mrq)0.82

Cash flow statement

Operating cash flow (ttm)153.94M
Levered free cash flow (ttm)142.17M